Maximiliano Hyon, DO
Endocrinology, Diabetes & Metabolism · Los Angeles, CANPI 1942626767
Payments from drug & device makers
Across 390 payments — averaging $64.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$18K
- Novo Nordisk$2K
- Lilly USA, LLC$769
- Boehringer Ingelheim$717
- Bayer$573
- Amgen$558
- plus $3K from 23 others
What the payments were for
- Speaking & faculty fees$15,91263%
- Travel & lodging$1,0134%
- Food & beverage$8,05432%
- Education$3451%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 47 | $18,269 |
| Novo Nordisk | 71 | $1,545 |
| Lilly USA, LLC | 35 | $769 |
| Boehringer Ingelheim | 24 | $717 |
| Bayer | 31 | $573 |
| Amgen(2 entities) | 37 | $558 |
| Recordati_rare_diseases_inc. | 20 | $461 |
| Insulet Corporation | 23 | $426 |
| Radius Health, Inc. | 24 | $255 |
| Corcept Therapeutics | 15 | $212 |
| Abbott | 9 | $209 |
| Ascendis Pharma Endocrinology Inc | 16 | $183 |
| Sanofi-aventis U.S. LLC | 4 | $179 |
| AstraZeneca | 4 | $179 |
| Valeritas, Inc. | 2 | $170 |
| Amarin Pharma, Inc. | 5 | $117 |
| Mannkind Corporation | 5 | $104 |
| Madrigal Pharmaceuticals | 2 | $70 |
| EUSA Pharma (US) LLC | 3 | $63 |
| Novartis | 2 | $55 |
| Medtronic(2 entities) | 2 | $43 |
| Sumitomo Pharma America, Inc. | 1 | $27 |
| Exact Sciences | 1 | $25 |
| Vistapharm, Inc. | 2 | $24 |
| Rhythm Pharmaceuticals, Inc. | 1 | $19 |
| Echosens North America, Inc. | 1 | $19 |
| Kyowa Kirin, Inc. | 1 | $18 |
| Sequel Med Tech, LLC | 1 | $16 |
| Tandem Diabetes Care, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM G6 TRANSMITTER$10,070
- DEXCOM G7 GSS (161)$7,201
- V-GO$125
- Tresiba$122
- Wegovy$122
- FARXIGA$116
- MOUNJARO$106
- PRALUENT$100
How this compares
$25,324 in reported general payments places this provider in the 80th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 676 | $837,209 |
| JardianceEmpagliflozin | 687 | $659,373 |
| MounjaroTirzepatide | 293 | $365,662 |
| KerendiaFinerenone | 224 | $218,576 |
| FarxigaDapagliflozin Propanediol | 144 | $150,798 |
| RybelsusSemaglutide | 112 | $149,338 |
| TrulicityDulaglutide | 88 | $133,142 |
| ProliaDenosumab | 43 | $72,129 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 93 | $54,271 |
| Tresiba Flextouch U-100Insulin Degludec | 138 | $51,611 |
| TymlosAbaloparatide | 18 | $45,578 |
| VascepaIcosapent Ethyl | 62 | $37,863 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 30 | $33,096 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 106 | $32,983 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 342 | $32,664 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,545 | $986,547788 claims |
| Boehringer IngelheimJardiance, Tradjenta | $717 | $679,929711 claims |
| Lilly USA, LLCMounjaro, Trulicity | $769 | $498,804381 claims |
| BayerKerendia | $573 | $218,576224 claims |
| AstraZenecaFarxiga | $179 | $150,798144 claims |
| AmgenProlia | $558 | $72,12943 claims |
| Radius Health, Inc.Tymlos | $255 | $45,57818 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 952 endocrinology, diabetes & metabolism providers in California.
Other endocrinology, diabetes & metabolism in Los Angeles
- Stanley HsiaLos Angeles$19.8M
- Shlomo MelmedLos Angeles$3.3M
- Sina TebiLos Angeles$2.4M
- Anthony HeaneyLos Angeles$788K
- Christian GastelumLos Angeles$421K
- Jerrold OlefskySan Diego$26.5M
- Mark ChristiansenWalnut Creek$22.9M
- Timothy BaileyEscondido$22.3M
- Juan FriasSan Diego$14.1M
- Paul NorwoodFresno$6.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.